Qritive inks multi-year deals for AI adoption in Indian Pathology

Qritive, a leading provider of AI solutions for pathology labs globally, has entered into partnerships with prominent diagnostic centres and hospitals in India, including Metropolis Healthcare, Rajiv Gandhi Cancer Institute, and CŌRE Diagnostics. These institutions have adopted Qritive's PantheonTM image management system (IMS) and AI products, positioning them as pioneers in incorporating artificial intelligence into pathology workflows. 

The collaboration aims to modernise pathology practices, leveraging AI to enhance diagnostic precision, streamline operational efficiency, and ultimately elevate patient care. Qritive's AI platform has demonstrated significant improvements in diagnosis speed and accuracy, with clinical studies indicating up to 90% faster diagnoses and 80% less discordance, particularly benefiting cancer patient care.

The partnerships signify a transformative journey for the diagnostic centres and hospitals, as they embrace AI technology to advance their capabilities in pathology. Metropolis Healthcare's CEO, Mr. Surendran Chemmenkottil, expresses enthusiasm for the potential of Qritive's AI-powered platform to revolutionise their workflows and contribute to setting new standards in cancer care, especially in effective treatment decision-making for prostate cancer detection.

The collaborations aim to strengthen diagnostic precision, improve patient outcomes, and potentially lead to the development of new AI services for the diagnosis of rare diseases, as highlighted by Mr. Dinesh Chauhan, CEO of CŌRE Diagnostics. Dr. Gurudutt Gupta from Rajiv Gandhi Cancer Institute emphasises the significant benefits Qritive's IMS and AI modules have brought to their pathology practice, enhancing workflow and diagnostic precision. Overall, the partnerships underscore the commitment to leveraging AI for the betterment of pathology practices and patient care.